AFL · Q1 2026 Earnings

Q2 FY2025 inflection candidate → Q3 FY2025 inflection validated → Q4 FY2025 inflection deferred → Q1 FY2026 reserve gains carry the print, disclosure pulled back

Three quarters ago management was expanding the disclosure framework; this quarter they quietly contracted it. In Q3 FY2025 management introduced segment-level pre-tax margin bands for both Japan and US — five new operational disclosures presented as a confidence signal. In Q4 FY2025 they were reaffirmed (with the Japan margin range stepped down, but still disclosed). This quarter all six US-side metrics plus two of three Japan-side metrics were not reiterated. The kept metric (Japan benefit ratio 60-63%) is the one most directly relevant to the reserve remeasurement story. The signal: management is willing to commit to ranges they have a clear forward read on, and is withdrawing where the forward read is murkier — but they did not explain the withdrawal, which is the issue.

The reinsurance narrative is being scaled up from a footnote to a strategic pillar. Last quarter reinsurance got passing mention as a capital-management tool. This quarter Max stated "over time, we certainly expect that this would be material to the company" on external reinsurance, while pairing it with "It will take time for this to build up" and Dan's anchor philosophy "What I like is evolution, not revolution." The introduction of a new strategic optionality theme — even hedged on timing — is the most genuinely new content of this call, though it remains unquantified.

Japan earned premium framing softened from explicit decline to vague flatness. Q4 FY2025 was the first quarter in four where management guided premium down (-1% to -2%). One quarter later that explicit guide is gone and replaced with the qualitative "we expect the 2026 sales to be equivalent to that of 2025 for Aflac Japan cancer insurance." Sales-equivalent ≠ earned-premium stable; the substitution dodges the harder question. Combined with Max's prior-quarter line that net earned premium growth in Japan is a "reasonable future" event, the trajectory of disclosure on this metric is getting less specific each quarter, not more.

Reserve remeasurement has now been disclosed as a meaningful EPS contributor in two consecutive segments. In Q3 FY2025 the favorable remeasurement was framed as a 130bps net-premium-ratio reduction — an embedded tailwind. In Q4 FY2025 management quietly raised the FY2026 Japan benefit ratio range even with that tailwind in run-rate. This quarter ~70bps Japan / ~80bps US above-plan remeasurement contributed $23M / $0.04 per share company-wide above plan. Management is now saying "we would expect going forward the favorable experience that we did have in this quarter to continue to generally have those trends in place" — a notable upgrade from prior framing that treated remeasurement as a one-time level shift. If sustained, this is real; if it reverses, the underlying underwriting margin is weaker than the headline ratios suggest.

Defensive regulatory framing surfaced for the first time. Management volunteered that they're seeing "no additional pressure from state regulators in the U.S. and no material impacts expected." Volunteering reassurance on an issue not previously discussed is itself the signal — something has been raised in conversations that prompted the proactive disclosure.